Although specific drug interaction studies have not been conducted with brimonidine tartrate ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. Because of the potential for serious adverse reactions from brimonidine tartrate ophthalmic solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If you are not completely satisfied, please contact us within 30 days.Heartland Veterinary Supply & Pharmacy is a .Pharmacy Accredited Pharmacy (Most common adverse reactions occurring in approximately 10% to 30% of patients receiving brimonidine ophthalmic solution 0.2% included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. The following reactions have been identified during postmarketing use of brimonidine tartrate ophthalmic solutions in clinical practice. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Brimonidine tartrate ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. It is an off- These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface [The preservative in brimonidine tartrate ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. The Heartland Staff is dedicated to fast, courteous service. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness. The protein binding of brimonidine has not been studied. Have coronary insufficiency or severe cardiovascular disease. 5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW= 442.24 To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc., at 1-800-932-5676 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Have hepatic or … Approximately 87% of an orally administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine. (One drop in the affected eye(s), three times daily, approximately 8 hours apart. After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours. (Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine tartrate ophthalmic solution 0.2% is supplied sterile, in white opaque plastic dropper bottles as follows: (Solution containing 2 mg/mL brimonidine tartrate. Brimonidine contraindications. Elevated IOP presents a major risk factor in glaucomatous field loss. Because brimonidine tartrate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution is advised. Located in Hastings, Nebraska, Heartland Veterinary Supply & Pharmacy started as a Veterinary Clinic in 1981, specializing in the health and wellness of the equine, canine and feline species. As with other similar medications, brimonidine tartrate ophthalmic solution may cause fatigue and/or drowsiness in some patients. The following serious adverse reactions are described elsewhere in the labeling: Approximately 20% were discontinued due to adverse experiences. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: